Anti-IL-17RA Antibody

Interleukin 17A (IL-17A) is a proinflammatory cytokine secreted by activated T-lymphocytes (1) . It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. IL-17RA is a ubiquitous type I membrane glycoprotein that binds with low affinity to IL-17A and IL-17F (1,2) . IL-17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis (3,4) . Defects in IL-17RA are the cause of familial candidiasis type 5 (CANDF5) which is a rare disorder with altered immune responses and impaired clearance of fungal infections (5) .

IL-17RA antibody is human, mouse and rat reactive. Multiple isoforms of IL-17RA are known to exist. This antibody is predicted to not cross-react with other IL-17 receptor subunits.

IL-17RA antibody was raised against an 18 amino acid peptide near the amino terminus of human IL-17RA. The immunogen is located within amino acids 150 - 200 of IL-17RA.

Receptor for IL17A (PubMed:17911633, PubMed:9367539) . Receptor for IL17F (PubMed:19838198, PubMed:17911633) . Binds to IL17A with higher affinity than to IL17F (PubMed:17911633) . Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC (PubMed:16785495) . Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC (PubMed:18684971) . Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848) . Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6 (PubMed:16785495, PubMed:17911633, PubMed:18684971) .